Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marc Milano

Emergency Medicine Berkeley Heights, NJ Medical Doctor

NPI 1477540219 CMS profile 157801

1 Diamond Hill Rd, Summit Medical Group, Berkeley Heights, NJ 07922

Open in the dashboard

General payments

$391,591

597 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marc Milano of Berkeley Heights, NJ is reported in the CMS Open Payments database as having received $391,591 across 597 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,287 18
2024 General $91,644 104
2023 General $118,855 187
2022 General $58,797 95
2021 General $60,552 98
2020 General $22,157 43
2019 General $27,298 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marc Milano
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to Marc Milano were reported at $12,287. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year Marc Milano Emergency Medicine median Middle half National median
2019 $27,298 $51 $18–$128 $163
2020 $22,157 $29 $16–$99 $114
2021 $60,552 $40 $18–$124 $132
2022 $58,797 $49 $20–$134 $149
2023 $118,855 $51 $22–$142 $160
2024 $91,644 $52 $22–$150 $164
2025 $12,287 $57 $24–$150 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $141,776 222 payments
  2. Gilead Sciences, Inc. $106,058 150 payments
  3. Chiesi USA, Inc. $51,107 55 payments
  4. AbbVie, Inc. $47,198 62 payments
  5. BioXcel Therapeutics, Inc. $31,093 59 payments
  6. Portola Pharmaceuticals, Inc. $9,951 16 payments
  7. AcelRx Pharmaceuticals, Inc. $2,285 2 payments
  8. Allergan Inc. $373 5 payments
  9. CSL Behring $261 3 payments
  10. Janssen Pharmaceuticals, Inc $246 7 payments
  11. Other $1,243 16 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $273,070 129 payments
  2. Travel and Lodging $43,902 200 payments
  3. Honoraria $39,920 22 payments
  4. Consulting Fee $18,970 6 payments
  5. Food and Beverage $15,720 239 payments
  6. Education $8 1 payment
Products named General payments · program years 2019–2025
  1. Veklury $105,281 129 payments
  2. LOKELMA $71,536 115 payments
  3. ANDEXXA Rare Disease $68,595 105 payments
  4. CLEVIPREX $49,416 50 payments
  5. DALVANCE $47,058 60 payments
  6. IGALMI $31,093 59 payments
  7. ANDEXXA Hematology/Neurology $9,951 16 payments
  8. DSUVIA $2,285 2 payments
  9. BREZTRI $1,685 1 payment
  10. CUROSURF $973 2 payments
  11. Other $3,205 37 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$9,341

Medicare's payments for the services billed

Medicare patients

60

Average age 67

Services billed

68

32 women, 28 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 62%
Heart failure 48%
Ischemic heart disease 48%
Arthritis 48%
Chronic kidney disease 47%
Depression 47%
COPD 38%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veklury
  • Gilead Sciences, Inc. $40,755
$40,755 — —
DALVANCE
  • AbbVie, Inc. $18,699
$18,699 — —
CLEVIPREX
  • CHIESI USA, INC. $11,415
$11,415 — —
IGALMI
  • BioXcel Therapeutics, Inc. $675
$675 — —
YUPELRI
  • Mylan Specialty L.P. $109
$109 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

597 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record